vs

Side-by-side financial comparison of COMMUNITY FINANCIAL SYSTEM, INC. (CBU) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

COMMUNITY FINANCIAL SYSTEM, INC. is the larger business by last-quarter revenue ($214.5M vs $151.7M, roughly 1.4× Tarsus Pharmaceuticals, Inc.). COMMUNITY FINANCIAL SYSTEM, INC. runs the higher net margin — 26.7% vs -5.5%, a 32.2% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 8.7%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 7.9%).

Community Health Systems (CHS) is a Fortune 500 company based in Franklin, Tennessee. It was the largest provider of general hospital healthcare services in the United States in terms of number of acute care facilities. In 2014, CHS had around 200 hospitals, but the number had declined to around 85 in 2021.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

CBU vs TARS — Head-to-Head

Bigger by revenue
CBU
CBU
1.4× larger
CBU
$214.5M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+119.7% gap
TARS
128.4%
8.7%
CBU
Higher net margin
CBU
CBU
32.2% more per $
CBU
26.7%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
7.9%
CBU

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CBU
CBU
TARS
TARS
Revenue
$214.5M
$151.7M
Net Profit
$57.2M
$-8.4M
Gross Margin
Operating Margin
-5.3%
Net Margin
26.7%
-5.5%
Revenue YoY
8.7%
128.4%
Net Profit YoY
15.3%
63.8%
EPS (diluted)
$1.15
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBU
CBU
TARS
TARS
Q1 26
$214.5M
Q4 25
$217.0M
$151.7M
Q3 25
$208.1M
$118.7M
Q2 25
$200.5M
$102.7M
Q1 25
$197.3M
$78.3M
Q4 24
$197.4M
$66.4M
Q3 24
$190.3M
$48.1M
Q2 24
$184.3M
$40.8M
Net Profit
CBU
CBU
TARS
TARS
Q1 26
$57.2M
Q4 25
$54.4M
$-8.4M
Q3 25
$55.1M
$-12.6M
Q2 25
$51.3M
$-20.3M
Q1 25
$49.6M
$-25.1M
Q4 24
$49.8M
$-23.1M
Q3 24
$43.9M
$-23.4M
Q2 24
$47.9M
$-33.3M
Operating Margin
CBU
CBU
TARS
TARS
Q1 26
Q4 25
33.1%
-5.3%
Q3 25
35.2%
-12.2%
Q2 25
32.9%
-21.6%
Q1 25
32.6%
-33.5%
Q4 24
32.7%
-36.8%
Q3 24
30.0%
-52.3%
Q2 24
33.7%
-81.6%
Net Margin
CBU
CBU
TARS
TARS
Q1 26
26.7%
Q4 25
25.1%
-5.5%
Q3 25
26.5%
-10.6%
Q2 25
25.6%
-19.8%
Q1 25
25.1%
-32.1%
Q4 24
25.2%
-34.8%
Q3 24
23.1%
-48.7%
Q2 24
26.0%
-81.6%
EPS (diluted)
CBU
CBU
TARS
TARS
Q1 26
$1.15
Q4 25
$1.03
$-0.17
Q3 25
$1.04
$-0.30
Q2 25
$0.97
$-0.48
Q1 25
$0.93
$-0.64
Q4 24
$0.94
$-0.57
Q3 24
$0.83
$-0.61
Q2 24
$0.91
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBU
CBU
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$572.2M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$2.0B
$343.4M
Total Assets
$17.5B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBU
CBU
TARS
TARS
Q1 26
$572.2M
Q4 25
$301.8M
$417.3M
Q3 25
$245.2M
$401.8M
Q2 25
$237.2M
$381.1M
Q1 25
$518.0M
$407.9M
Q4 24
$197.0M
$291.4M
Q3 24
$346.1M
$317.0M
Q2 24
$201.5M
$323.6M
Total Debt
CBU
CBU
TARS
TARS
Q1 26
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$990.2M
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Stockholders' Equity
CBU
CBU
TARS
TARS
Q1 26
$2.0B
Q4 25
$2.0B
$343.4M
Q3 25
$1.9B
$335.1M
Q2 25
$1.9B
$332.6M
Q1 25
$1.8B
$342.5M
Q4 24
$1.8B
$224.5M
Q3 24
$1.8B
$237.5M
Q2 24
$1.7B
$252.2M
Total Assets
CBU
CBU
TARS
TARS
Q1 26
$17.5B
Q4 25
$17.3B
$562.2M
Q3 25
$17.0B
$534.6M
Q2 25
$16.7B
$495.0M
Q1 25
$16.8B
$500.8M
Q4 24
$16.4B
$377.0M
Q3 24
$16.4B
$376.3M
Q2 24
$15.9B
$376.8M
Debt / Equity
CBU
CBU
TARS
TARS
Q1 26
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.56×
0.32×
Q3 24
0.30×
Q2 24
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBU
CBU
TARS
TARS
Operating Cash FlowLast quarter
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBU
CBU
TARS
TARS
Q1 26
Q4 25
$301.9M
$19.3M
Q3 25
$101.1M
$18.3M
Q2 25
$53.7M
$-29.4M
Q1 25
$62.5M
$-20.7M
Q4 24
$242.3M
$-22.2M
Q3 24
$56.9M
$-8.7M
Q2 24
$39.8M
$-14.4M
Free Cash Flow
CBU
CBU
TARS
TARS
Q1 26
Q4 25
$233.3M
$13.0M
Q3 25
$83.4M
$16.3M
Q2 25
$36.4M
$-30.4M
Q1 25
$52.0M
$-21.2M
Q4 24
$221.6M
$-22.3M
Q3 24
$51.9M
$-8.9M
Q2 24
$33.8M
$-15.4M
FCF Margin
CBU
CBU
TARS
TARS
Q1 26
Q4 25
107.5%
8.6%
Q3 25
40.1%
13.8%
Q2 25
18.1%
-29.6%
Q1 25
26.3%
-27.1%
Q4 24
112.2%
-33.5%
Q3 24
27.3%
-18.6%
Q2 24
18.3%
-37.8%
Capex Intensity
CBU
CBU
TARS
TARS
Q1 26
Q4 25
31.6%
4.2%
Q3 25
8.5%
1.6%
Q2 25
8.6%
1.0%
Q1 25
5.3%
0.8%
Q4 24
10.5%
0.1%
Q3 24
2.6%
0.6%
Q2 24
3.3%
2.5%
Cash Conversion
CBU
CBU
TARS
TARS
Q1 26
Q4 25
5.55×
Q3 25
1.84×
Q2 25
1.05×
Q1 25
1.26×
Q4 24
4.87×
Q3 24
1.30×
Q2 24
0.83×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons